Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
about
Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer.Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy.Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico.
P2860
Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Pathological responses and sur ...... therapy including trastuzumab.
@en
Pathological responses and sur ...... therapy including trastuzumab.
@nl
type
label
Pathological responses and sur ...... therapy including trastuzumab.
@en
Pathological responses and sur ...... therapy including trastuzumab.
@nl
prefLabel
Pathological responses and sur ...... therapy including trastuzumab.
@en
Pathological responses and sur ...... therapy including trastuzumab.
@nl
P2093
P2860
P1433
P1476
Pathological responses and sur ...... therapy including trastuzumab.
@en
P2093
Hideyuki Ohzawa
Takashi Sakatani
Toshiro Niki
Yasuo Hozumi
Yoshikazu Yasuda
P2860
P2888
P304
P356
10.1007/S12282-012-0424-4
P577
2012-10-30T00:00:00Z